BOBULSKY SUSAN sold $193K of ADPT
BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 6,444 shares of Adaptive Biotechnologies Corp (ADPT) at $30.00 ($0.19M total) on 2026-10-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides incremental transparency on insider liquidity activity but does not indicate a new business, clinical, or regulatory catalyst.
Market read
A routine 10b5-1 insider sale is unlikely to drive a sustained repricing by itself.
What to watch
10b5-1 plans reduce interpretability; the sale price ($30) may reflect the plan’s execution window rather than a new view on valuation.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies.
Ticker impact
Adaptive Biotechnologies Form 4 shows CCO Susan Bobulsky sold 6,444 shares at $30.00 on 2026-10-06 under a 10b5-1 plan.
Likely limited near-term impact, with any move more driven by broader biotech sentiment than this transaction.
The filing is a routine insider sale with stated 10b5-1 pre-arrangement; the disclosed dollar value is not large enough to be a standalone fundamental reset.
Market effects
Minimal, as this is company-specific insider activity without disclosed operational or regulatory changes.
None.
None.
Counterpoint
Traders may treat repeated insider sales as a weak confidence signal, especially if paired with other negative company-specific developments not mentioned here.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider sale by its Chief Commercial Officer.
- insiderSusan Bobulsky
Chief Commercial Officer, MRD, who sold shares under a 10b5-1 plan.
